Skip to main navigation
Skip to search
Skip to main content
Hamad Bin Khalifa University Home
Home
Profiles
Research units
Projects
Research output
Student theses
Search by expertise, name or affiliation
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group
Qatar Computing Research Institute
Research output
:
Contribution to journal
›
Article
›
peer-review
250
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Imdevimab
100%
Casirivimab
100%
Antibody Status
15%
Antibodies to SARS-CoV-2
7%
Proportional Effect
7%
Intravenous Infusion
7%
Serious Adverse Reaction
7%
Viral Entry
7%
One Dose
7%
Major Bleeding Events
7%
Safety Outcomes
7%
UK Hospitals
7%
Antibody Combinations
7%
SARS-CoV-2 Vaccine
7%
Laboratory Confirmation
7%
Humoral Immune Response
7%
SARS-CoV-2 Spike Glycoprotein
7%
Immunology and Microbiology
Viral Entry
25%
Humoral Immunity
25%
All Cause Mortality
25%
Pharmacology, Toxicology and Pharmaceutical Science
Thrombosis
33%